Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.404 Factor de Impacto de 5 años: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumes:
Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v35.i5.50
pages 417-432

Role of CD38 Expression in Diagnosis and Pathogenesis of Chronic Lymphocytic Leukemia and Its Potential as Therapeutic Target

Simone Burgler
Experimental Infectious Diseases and Cancer Research, University Children's Hospital Zurich, 8008 Zurich, Switzerland

SINOPSIS

CD38 is widely accepted as a marker for unfavorable prognosis in chronic lymphocytic leukemia (CLL). Nevertheless, its direct contribution to the disease pathogenesis is not very well understood. Recent data indicate that CD38 may promote CLL pathogenesis by enhancing proliferation in synergy with B-cell receptor (BCR) signaling and by supporting migration and homing of CLL cells to secondary lymphoid organs, where the malignant cells receive support from the tumor microenvironment. CD38 may also contribute to a suppressed anticancer immune response through the production of tolerogenic compounds. This review first shortly summarizes the biology, expression, and function of CD38 in general and in CLL cells in more detail. Next, the current literature and open questions regarding a direct contribution of CD38 to CLL pathogenesis are critically reviewed. Finally, I discuss the potential of CD38 as therapeutic target in light of its possible roles in CLL and the promising results of clinical trials with CD38 antibodies in multiple myeloma (MM)


Articles with similar content:

The Proteasome and Its Inhibitors in Immune Regulation and Immune Disorders
Critical Reviews™ in Immunology, Vol.26, 2006, issue 6
Alberto Ballestrero, Franco Patrone, Frank Grunebach, Alessio Nencioni, Peter Brossart
ANP-NPRA Signaling Pathway−A Potential Therapeutic Target for the Treatment of Malignancy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.23, 2013, issue 2
Jia Zhang, Jiansheng Wang, Ya Yang, Kai Sun, Zhilong Zhao, Min Li
The Immune System in the Pathogenesis of Ovarian Cancer
Critical Reviews™ in Immunology, Vol.33, 2013, issue 2
Ellen L. Goode, Kimberly R. Kalli, Keith L. Knutson, Melissa S. DeRycke, Bridget Charbonneau
Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 3-4
Crystal L. Mackall, Rimas J. Orentas
Natural Products as Inhibitors of Epidermal Growth Factor Receptor
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth